Lenvatinib in anaplastic thyroid cancer
Statement of the Problem: Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor (TKI) of VEGFR1-VEGFR3, FGFR1FGFR4, PDGFRÃ?±, RET and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog ... signaling…

